

CERVICAL CANCER SCREENING USING VISUAL INSPECTION WITH ACETIC ACID AND IODINE (VIA/VILI) BY A NON-GOVERNMENTAL ORGANIZATION IN RIVERS STATE, NIGERIA.

Okoh DorothyA^{1*}, Iwo-AmahR², Briggs NCT³, Ununuma Oguzor⁴

¹Preventive Healthcare Initiative

²Department of Obstetrics and Gynaecology, Rivers State University Teaching Hospital, Port Harcourt, Nigeria

³Department of Community Medicine, Rivers State University, Nigeria

⁴Department of Family Medicine, Rivers State University Teaching Hospital, Port Harcourt, Nigeria

ABSTRACT

Background: Cervical cancer is the fourth most common cancer among women worldwide, with the highest burden in low- and middle-income countries (LMICs) where it is the second most common cancer in women. Nearly 90% of the estimated 570,000 new cases and 311,000 deaths in 2018 occurred in LMICs.

Aim/Objective: The objective of the program was to promote cervical cancer awareness and early detection strategies including the introduction of Visual Inspection with Acetic Acid (VIA) and Iodine (VILI) as screening tools among our women.

Method: This was a cross-sectional study a reflective analysis of the VIA/VILI result of 101 women who participated in a cervical cancer awareness and screening community outreach organized by Preventive Health Care Initiative, a nongovernmental organization in Rivers State, Nigeria. A structured survey form was administered to all the women who consented to screening (after explanation of the procedure). The data was coded and analysis was performed in simple statistical method.

Results: The age range of women screened was between 19 and 73 years with a mean age of 39 years and 82 (81%) were within the reproductive age. Sixty six (65%) of the women had tertiary education while thirty and three of them had secondary and primary education respectively, only two women had no formal education.

Majority of the women 56 (55%) were married while 35 (32%) were single and 10 (9%) were widows. The average age of participants at first sexual exposure was 20 years with 25 (23%) commencing sexual activity before 18 years. Forty one (37%) of the women were grand multiparous, only eighteen (16%) claimed never to have been pregnant. There were 15 (15%) VIA /VILI positive cases and 3 (2.7%) were clinically suspicious of invasive cervical cancer.

Conclusion: The study revealed that there were 15 (15%) VIA /VILI positive cases and 3 (2.7%) were clinically suspicious of invasive cervical cancer. In addition, the study revealed the average age at coitarche was 20 years.

Key words: Cervical cancer, Screening, Preventive Healthcare Initiative, Nigeria.

Corresponding Author:
daokoh@gmail.com

Receiving Date: February 24, 2021

Acceptance Date: March 21, 2021

Publication Date: March 26, 2021

INTRODUCTION

Cervical cancer is the fourth most common cancer among women worldwide, with the highest burden in low- and middle-income countries (LMICs) where it is the second most common cancer in women [1-4]. Nearly 90% of the estimated 570,000 new cases and 311,000 deaths in 2018 occurred in LMICs [1-2]. Cervical cancer is a largely preventable, but remains a major cause of cancer

related death in low- and middle-income countries (LMICs), where resources for effective prevention and screening programs are scarce and inaccessible. Nearly 80% of cervical cancer cases in LMICs like Nigeria present with advanced-stage invasive cervical cancer, with high morbidity and mortality [1,5], whereas the incident and mortality rates are almost 6-7 times lesser in High-Income Countries (HIC) [6].

The preventive strategies are based on the established knowledge that nearly all cases of cervical cancer are attributable to persistent Human Papilloma Virus (HPV) Infection [7]. The infection is naturally followed by a predictive course of progression from mild dysplasia to invasive cancer over 10-20 years [7,8]. Thus, justifying the rationale for cervical cancer prevention through HPV vaccination, screening and treatment of precancerous lesions. Additionally, primary prevention can also be achieved through health promotional activities that involve community education about cervical cancer and risk reduction strategies that are culturally appropriate. This is particularly important in LMICs, where several studies have shown poor knowledge of the disease [9] and HPV vaccine is inaccessible and vaccination coverage is poor [1-4]. Secondary prevention strategy like cervical screening subsequently should be adopted in battling the cervical cancer burden in LMICs [13]. The recommended screening tests include cytology (Conventional (Pap smear) and Liquid based), HPV- DNA testing, and Visual Inspection with either Acetic Acid (VIA) or Lugol's Iodine (VILI) or both.

In High Income Countries (HICs) over 80% decline in cervical cancer has been achieved through organised screening cytology-based programme. Whereas, in LMICs cytology-based screening has remained ineffective, with poor coverage. In view of the failure of cytology -based screening programmes, the World Health Organization recommended visual inspection (VIA/VILI) as alternative screening method in LMICs [3-4]. The method is easier to perform, accurate, cost-effective and the results are instant which allows treatment at a sitting [1-4]

Several studies have also shown that visual inspection demonstrated a close diagnostic accuracy to cytology, [2,4] and already adopted by twenty-six countries [4].

In Nigeria, with an estimated 14,943 new cases and 10,403 deaths annually, the cytology-based screening uptake is relatively low, essentially due to inadequate resources in running an organised national prevention program for women [1,3],[9-11].

It is against this backdrop that the Preventive Healthcare Initiative organised a cervical cancer awareness and early detection outreach at the Amadi Polytechnic Medical Centre, Rumuadolu, Port Harcourt. The program was preceded by a week-long public enlightenment and awareness campaigns on social media, radio and television. The objective of the program was to promote cervical cancer awareness and early detection strategies including the introduction of Visual Inspection with Acetic Acid (VIA) and Iodine (VILI) as screening tools among our women.

METHOD

This study is a reflective analysis of the VIA/VILI result of 101 women who participated in a cervical cancer awareness and screening community outreach organised by Preventive Health Care Initiative, a nongovernmental organization in Rivers State, Nigeria. Following the preliminary cervical cancer education session, a structured survey form was administered to all the women who consented to screening (after explanation of the procedure). All the participants were asked to respond to questions related to their age, educational level, last menstrual period (LMP), first sexual exposure, marital status, parity and complaints related to cervical cancer. The screening method was visual inspection with acetic acid (VIA) and Lugol's iodine (VILI). The procedure and interpretation of results were as directed in the WHO manual (A Practical Manual on Visual Screening for Cervical Neoplasia). The procedure was well tolerated by the participant with no complaints.

The Interpretation of the VIA and VILI colour changes were both classified as negative, positive, or suspicious (clinically suspicious cases of invasive cancer). The VIA colour changes were recorded as positive (for aceto white lesion at the squamo-columnar junction), negative (no aceto-white lesion).

Results were classified as suspicious when the lesions macroscopically suspicious cases of invasive cancer. The analysis was performed in simple statistical method.

RESULTS

The age range of women screened was between 19 and 73 years with a mean age of 39 years and 82 (81%) were within the reproductive age. Sixty six (65%) of the women had tertiary education while thirty and three of them

had secondary and primary education respectively, only two women had no formal education.

Majority of the women 56 (55%) were married while 35 (32%) were single and 10 (9%) were widows. The average age of participants at first sexual exposure was 20 years with 25 (23%) commencing sexual activity before 18 years. Forty one (37%) of the women were grand multiparous, only eighteen (16%) claimed never to have been pregnant. There were 15 (15%) VIA /VILI positive cases and 3 (2.7%) were clinically suspicious of invasive cervical cancer. All positive cases were referred to Rivers State University Teaching Hospital and successfully navigated for further investigation and received appropriate treatment and follow up.

DISCUSSION

This study was carried out by Preventive Health Care Initiative, a nongovernmental organization in Rivers State, Nigeria. The analysis from the study showed that 15% of the populace were positive for VIA/VILLI. This result was lower than the upper limit of 25% by the study done by Ajenifuja KO et al in a population-based study in rural Nigeria [9]. Furthermore, in another cross-sectional study by Stravasta et al in India over an eighteen month period revealed that 21.38% that were screened for cervical cancer using VIA were positive, this was higher than the result of 15% from our study. However, in a study in Ethiopia by Hailemariam G et al was 9% for the positive VIA screening for the populace that were screened for cervical cancer which was not in agreement with our study [11]. The challenges of screening with VIA/VILLI are myriad; though the World Health Organization (WHO) recommends screening for cervical cancer using the human papillomavirus DNA testing.[12]. This recommendation is based on the fact that this testing modality is more sensitive and detects precancerous and cancers compared to VIA/VILLI [12-13]. However, human papillomavirus screening is not widely available in Nigeria and many other developing countries of the world [12-16]. For this reason the WHO allows alternative screening modality of VIA/VILLI as part of “screen and treat” as an inexpensive as well as a simple procedure by trained health personnel thus give a wider screening coverage [12][18-20]. However, issues such as false positivity and over treatment are challenges with VIA/VILLI due to subjectivity and variability in the interpretation of results between health care providers [12-14]. For low resource settings like ours options of treatment during screening with VIA/VILLI include cryotherapy using nitrous oxide or in some other settings using carbon dioxide for precancerous lesions [12-16]. In addition, more recent modality for treatment in “screen and treat” using VIA/VILLI is the use of thermal ablation as suitable for low-resource setting [12-15]. The reason for this recommendations by WHO is base on the use of light weight equipment, short treatment time and the use of hand-held battery operated and solar powered models [12-16]. The study revealed that majority of the respondents 66% had tertiary level of education this is in agreement with studies done in urban cities in the country,[9-14][18-20] this figure is shown in **Table 1** and **pie-chart**.

Table 1: Distribution of the level of educational status of respondents

| Level of education | Frequency (%) |
|---------------------|-------------------|
| No formal education | 2 (2 %) |
| Primary | 3 (3 %) |
| Secondary | 30 (30%) |
| Tertiary | 66 (65%) |
| Total | 110 (100%) |




Figure 1 : Distribution of educational status of the respondents

Primary – 2 (2%) Blue
Secondary – 30 (30%) Grey
Tertiary – 66 (65%) Brown
No formal education – 2 (2%) Yellow,,
Total = 110 (100%)

CONCLUSION

The study revealed that there were 15 (15%) VIA /VILI positive cases and 3 (2.7%) were clinically suspicious of invasive cervical cancer. In addition, the study revealed the average age at coitarche was 20 years. Enlightenment campaign by the government and nongovernmental organisations is highly recommended as well as organized screening modalities for at risk persons for cervical cancer to prevent morbidities and mortalities from the disease condition.

RECOMMENDATION

All the whose had negative results were counselled based on the SOGON/National screening recommendation for negative (VIA/VILI) results. All positive cases were however referred to Rivers State University Teaching Hospital and successfully navigated for further investigation and received appropriate treatment and follow up. Large scale study with larger sample size is recommended. There was no conflict of interest.

REFERENCES

1. World Health Organization. Cervical Cancer <https://www.who.int/cancer/prevention/diagnosis-screening/cervicalcancer/en/>. Accessed February 11, 2019.
2. Seleye-Fubara O, Uzoigwe SA. Pattern of primary female genital cancer in Port Harcourt, Nigeria. A 12-year review. *Sahel Med J* 2003; 6: 34-9.
3. Anorlu RI. Cervical cancer: The sub-saharan African perspective. *Reproductive Health Matters* 2008; 16:41-9.
4. Siegel RL, Miller KD, Jemal A. *Cancer J Clin* 2020; 70: 7-30.
5. Udofia E, Awaoro CD, Ekanem U. Awareness, use and main source of information on preventive health examinations: a survey of childbearing women in Uyo, Nigeria. *African Journal of Reproductive Health* 2012; 16(4): 149-61.
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. *Cancer Incidence and Mortality Worldwide: IARC. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10*

- [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: URL: <http://globocan.iarc.fr> 5
7. World Health Organization (WHO). WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. WHO, 2013? http://apps.who.int/iris/bitstream/10665/94830/1/9789241548694_eng.pdf
 8. Anorlu RI, Cervical cancer: the sub-Saharan African perspective *Reproductive Health Matters* 2008;16(32):41–49.
 9. Ajenifuja KO et al. A population-based study of visual inspection with acetic acid (VIA) for cervical screening in rural Nigeria. *Int J Gynecol Cancer* 2013; 23(3):507-12.
 10. Strivastava A et al. Visual Inspection with Acetic Acid Versus Papanicolaou Test in Cervical Screening. *Indian J Gynecol Oncolog* 2020;18:86. <https://doi.org/10.1007/s40944-020-00438-z>.
 11. Hailemariam G et al. Magnitude and associated factors of VIA positive test results for cervical cancer screening among refugee women aged 25-49 years in North Ethiopia. *BMC Cancer* 2020;20:858. <https://doi.org/10.1186/s12885-200-07344-9>
 12. Kari, P.B., & Marc, R.L. Human Papillomavirus (HPV), HPV-Related Disease, and the HPV Vaccine . *Rev ObstetGynecol*, 1(1), 2–10. (2008).
 13. Okunowo AA, Smith-Okonu ST. Cervical cancer screening among urban Women in Lagos, Nigeria. Focus on barriers and motivators for screening. *Niger J Gen Pract* 2020; 18: 10–6.
 14. Desai KT, Ajenifuja KO, Banjo A et al. Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage. *Infect Agents Cancer* 2020; 15: 60. <https://doi.org/10.1186/s13027-020>.
 15. Porras C et al. Performance of Self-collected Cervical Samples in Screening for Future Precancer using Human Papillomavirus DNA Testing. *J Natl Cancer Inst.* 2015; 107(1): 1-9.
 16. Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. *Eur J Cancer* 2013; 49(15): 3262-73.
 17. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015;136:(5): E359-86.
 18. Anyasi H, Foss AM. A comparative analysis of cervical cancer prevention between Nigeria and Nordic countries that have experienced a decline in cervical cancer incidence. *International Health*, 2020; ihaa062. <https://doi.org/10.1093/inthealth/haa062>.
 19. Schiffman M, Castle PE, Jeronimo J et al. Human papillomavirus and cervical cancer. *Lancet.* 2007; 370:890-907.
 20. Eze JN, Emeka-Irem EN, Edegbe FO. A six-year study of the clinical presentation of cervical cancer and management challenges encountered at a state teaching hospital in southeast Nigeria. *Clin Med Insights Oncol.* 2013; 7:151-8.
 21. Peto J, Gilham C, Fletcher O et al. The cervical cancer epidemic that screening has prevented in the UK. *Lancet* 2004;364(9430):249-56.
 22. Kim JJ, Brisson M, Edmunds WJ et al. Modeling cervical cancer prevention in developed countries. *Vaccine* 2008; 26(Suppl 10):K76-86.
 23. Schiffmann M, Castle PE. The promise of global cervical cancer prevention. *N Engl Med* 2005; 353(20):2101-4.